Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2018-01-30

Clinical Trial Update: Lesinurad and Febuxostat Combination Extension Study in Gout [Phase 3]

View source ↗

Summary

Phase 3 trial update for a lesinurad and febuxostat combination in gout has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • FEBUXOSTAT (Febuxostat)
  • Lesinurad (lesinurad)

Snippet

Sponsor: Ardea Biosciences, Inc. | Conditions: Gout | Phase 3 | Status: COMPLETED | Results posted: 2018-01-30